Xvivo Perfusion Financials
| XVIVO Stock | SEK 457.50 7.00 1.51% |
Xvivo |
Understanding current and past Xvivo Perfusion Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Xvivo Perfusion's financial statements are interrelated, with each one affecting the others. For example, an increase in Xvivo Perfusion's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Xvivo Perfusion's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xvivo Perfusion AB. Check Xvivo Perfusion's Beneish M Score to see the likelihood of Xvivo Perfusion's management manipulating its earnings.
Xvivo Perfusion Stock Summary
Xvivo Perfusion competes with Vitrolife, BioArctic, CellaVision, Invisio Communications, and Hexatronic Group. Xvivo Perfusion AB , a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. Xvivo Perfusion AB was founded in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 45 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0004840718 |
| Business Address | MAessans gata 10, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.xvivoperfusion.com |
| Phone | 46 3 17 88 21 50 |
| Currency | SEK - Swedish Kronor |
You should never invest in Xvivo Perfusion without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Xvivo Stock, because this is throwing your money away. Analyzing the key information contained in Xvivo Perfusion's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Xvivo Perfusion Key Financial Ratios
There are many critical financial ratios that Xvivo Perfusion's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Xvivo Perfusion AB reports annually and quarterly.| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Target Price | 383.33 | |||
| Number Of Employees | 133 | |||
| Beta | 1.97 |
Xvivo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xvivo Perfusion's current stock value. Our valuation model uses many indicators to compare Xvivo Perfusion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xvivo Perfusion competition to find correlations between indicators driving Xvivo Perfusion's intrinsic value. More Info.Xvivo Perfusion AB is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Xvivo Perfusion AB is roughly 2.39 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xvivo Perfusion's earnings, one of the primary drivers of an investment's value.Xvivo Perfusion AB Systematic Risk
Xvivo Perfusion's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Xvivo Perfusion volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Xvivo Perfusion AB correlated with the market. If Beta is less than 0 Xvivo Perfusion generally moves in the opposite direction as compared to the market. If Xvivo Perfusion Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Xvivo Perfusion AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Xvivo Perfusion is generally in the same direction as the market. If Beta > 1 Xvivo Perfusion moves generally in the same direction as, but more than the movement of the benchmark.
Xvivo Perfusion November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Xvivo Perfusion help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Xvivo Perfusion AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Xvivo Perfusion AB based on widely used predictive technical indicators. In general, we focus on analyzing Xvivo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Xvivo Perfusion's daily price indicators and compare them against related drivers.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 12.19 | |||
| Value At Risk | (3.34) | |||
| Potential Upside | 3.0 |
Additional Tools for Xvivo Stock Analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.